RxDoctor Payments Data

Leslie Swanson

Adult Health · Seattle, WANPI 1912376591

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $15,778 of the $17,717 with a category attached, or 89.1%. Astellas Pharma Global Development accounts for 80.1% of it on its own, with 5 other manufacturers making up the rest. Among adult health clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$17,717in general payments, 2019–2025

Across 15 payments — averaging $1181.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma Global Development$14K
  • Lilly USA, LLC$1K
  • Array Biopharma Inc$1K
  • Ipsen Biopharmaceuticals, Inc$921
  • Tempus AI, Inc$123
  • Foundation Medicine, Inc.$112

What the payments were for

  • Consulting fees$15,77889%
  • Speaking & faculty fees$8005%
  • Travel & lodging$6544%
  • Food & beverage$4853%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,717 in reported general payments places this provider in the 95th percentile of 252 adult health providers in Washington.

See all adult health providers in Washington

Medicare billing

Part B allowed, 2024
$51,042
Medicare patients
124
Services billed
630

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase64$187,202
EliquisApixaban36$26,769
Oxycodone Hcl50$1,327
Morphine Sulfate ErMorphine Sulfate26$846
Ondansetron OdtOndansetron28$677
Omeprazole48$503
LoperamideLoperamide Hcl25$467
Dexamethasone52$444
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine19$414
Hydromorphone Hcl13$392
Prochlorperazine Maleate19$360
Olanzapine17$344
Potassium Chloride25$329
Mirtazapine25$227
Ondansetron Hcl18$225

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCOlanzapine$1,200$34417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 252 adult health providers in Washington.

Other adult health in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →